Poly(C)-binding Protein 2 Regulates the p53 Expression via Interactions with the 5'-Terminal Region of p53 mRNA.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Dec 2021
Historique:
received: 10 11 2021
revised: 03 12 2021
accepted: 07 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 11 1 2022
Statut: epublish

Résumé

The p53 protein is one of the major transcriptional factors which guards cell homeostasis. Here, we showed that poly(C)-binding protein 2 (PCBP2) can bind directly to the 5' terminus of p53 mRNA by means of electrophoretic mobility shift assay. Binding sites of PCBP2 within this region of p53 mRNA were mapped using Pb2+-induced cleavage and SAXS methods. Strikingly, the downregulation of PCBP2 in HCT116 cells resulted in a lower level of p53 protein under normal and stress conditions. Quantitative analysis of p53 mRNA in PCBP2-downregulated cells revealed a lower level of p53 mRNA under normal conditions suggesting the involvement of PCBP2 in p53 mRNA stabilisation. However, no significant change in p53 mRNA level was observed upon PCBP2 depletion under genotoxic stress. Moreover, a higher level of p53 protein in the presence of rapamycin or doxorubicin and the combination of both antibiotics was noticed in PCBP2-overexpressed cells compared to control cells. These observations indicate the potential involvement of PCBP2 in cap-independent translation of p53 mRNA especially occurring under stress conditions. It has been postulated that the PCBP2 protein is engaged in the enhancement of p53 mRNA stability, probably via interacting with its 3' end. Our data show that under stress conditions PCBP2 also modulates p53 translation through binding to the 5' terminus of p53 mRNA. Thus PCBP2 emerges as a double-function factor in the p53 expression.

Identifiants

pubmed: 34948101
pii: ijms222413306
doi: 10.3390/ijms222413306
pmc: PMC8708005
pii:
doi:

Substances chimiques

5' Untranslated Regions 0
PCBP2 protein, human 0
RNA-Binding Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Polish National Centre of Science
ID : 2016/21/B/NZ1/02832

Références

RNA. 2019 Jul;25(7):757-767
pubmed: 31010886
Oncotarget. 2016 Apr 12;7(15):19483-98
pubmed: 26761212
RNA Biol. 2012 Dec;9(12):1429-39
pubmed: 23131771
Mol Cell Biol. 2003 Oct;23(20):7083-95
pubmed: 14517280
J Biol Chem. 2012 May 11;287(20):16467-76
pubmed: 22433872
Mech Ageing Dev. 2014 Jul;139:11-21
pubmed: 24915467
Nucleic Acids Res. 2012 Jun;40(11):5101-14
pubmed: 22344691
Cell. 2005 Dec 16;123(6):1065-78
pubmed: 16360036
Sci Rep. 2016 Apr 26;6:25205
pubmed: 27112540
RNA. 2017 Nov;23(11):1712-1728
pubmed: 28821580
Biochemistry. 2011 Aug 23;50(33):7080-92
pubmed: 21770379
J Virol. 2007 Sep;81(17):8919-32
pubmed: 17581994
Oncogene. 2014 Jan 30;33(5):611-8
pubmed: 23318444
FEBS J. 2019 Jun;286(12):2415-2428
pubmed: 30873718
Int J Mol Sci. 2017 Jan 04;18(1):
pubmed: 28054974
Nucleic Acids Res. 2012 Aug;40(14):e112
pubmed: 22539264
Eur J Biochem. 1992 Mar 1;204(2):575-81
pubmed: 1541273
Nucleic Acids Res. 2016 Mar 18;44(5):2409-16
pubmed: 26743003
Exp Mol Med. 2018 Feb 9;50(2):e441
pubmed: 29422543
J Biol Chem. 2001 May 18;276(20):17484-96
pubmed: 11278705
RNA Biol. 2019 Jan;16(1):25-41
pubmed: 30518296
Eur J Biochem. 1996 Oct 15;241(2):425-31
pubmed: 8917439
Mol Cell Biol. 1999 Jul;19(7):4572-81
pubmed: 10373506
Mol Cell Biol. 2003 Jan;23(2):708-20
pubmed: 12509468
Cell Rep. 2020 Mar 31;30(13):4355-4369.e6
pubmed: 32234473
Sci Rep. 2018 Jan 24;8(1):1533
pubmed: 29367734
Genes Dev. 2008 Dec 15;22(24):3449-60
pubmed: 19141477
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27413116
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5401-6
pubmed: 17372198
RNA Biol. 2013 Nov;10(11):1726-40
pubmed: 24418891
Oncogene. 2004 Apr 19;23(18):3200-7
pubmed: 15094769
IUCrJ. 2017 Apr 10;4(Pt 3):271-282
pubmed: 28512574
J Mol Cell Biol. 2019 Apr 1;11(4):284-292
pubmed: 30500901
Acta Biochim Pol. 2016;63(4):645-651
pubmed: 27776193
Cancers (Basel). 2011 Mar 03;3(1):994-1013
pubmed: 24212651
Epigenetics. 2011 Sep 1;6(9):1068-77
pubmed: 21814038
J Clin Invest. 2013 May;123(5):2103-18
pubmed: 23585479
Nucleic Acids Res. 2019 Apr 23;47(7):3257-3271
pubmed: 30828720
RNA Biol. 2020 Oct;17(10):1402-1415
pubmed: 32449427
J Virol. 2000 Mar;74(5):2219-26
pubmed: 10666252
Q Rev Biophys. 2007 Aug;40(3):191-285
pubmed: 18078545
PLoS One. 2021 Sep 7;16(9):e0256938
pubmed: 34492050
Biomed Res Int. 2015;2015:708158
pubmed: 26273641
Nucleic Acids Res. 2003 Jul 1;31(13):3381-5
pubmed: 12824332
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Oncogene. 2003 Sep 11;22(39):8012-20
pubmed: 12970749
RNA. 2004 Aug;10(8):1266-76
pubmed: 15247434
J Mol Cell Biol. 2019 Oct 25;11(10):911-919
pubmed: 31504667
Genes Dev. 2010 Oct 1;24(19):2146-56
pubmed: 20837656
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2410-4
pubmed: 9122208
Cell Cycle. 2008 Jul 15;7(14):2189-98
pubmed: 18635961
RNA. 2002 Mar;8(3):265-78
pubmed: 12003487
RNA. 1997 Oct;3(10):1124-34
pubmed: 9326487
Neurochem Res. 2016 Sep;41(9):2401-14
pubmed: 27209304
Mol Cancer Res. 2003 Apr;1(6):463-74
pubmed: 12692266
FEBS Lett. 2004 Nov 5;577(1-2):134-40
pubmed: 15527774
J Biol Chem. 2008 Oct 17;283(42):28757-66
pubmed: 18701464
Eur J Biochem. 1995 Jun 1;230(2):447-53
pubmed: 7607214
Acta Biochim Pol. 2016;63(4):737-744
pubmed: 27741327
Int J Mol Sci. 2019 Oct 29;20(21):
pubmed: 31671760
J Biol Chem. 2016 Apr 29;291(18):9629-37
pubmed: 26907686
Cell. 2005 Oct 7;123(1):49-63
pubmed: 16213212
Nucleic Acids Res. 2020 Aug 20;48(14):8006-8021
pubmed: 32556302
PLoS One. 2013 Nov 11;8(11):e78863
pubmed: 24244378
PLoS One. 2015 Oct 29;10(10):e0141676
pubmed: 26513723
Mol Cell Oncol. 2020 Jun 23;7(5):1767483
pubmed: 32944629
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11115-20
pubmed: 8855318
J Virol. 1997 Aug;71(8):6243-6
pubmed: 9223526
Mol Cell. 2018 Jun 7;70(5):854-867.e9
pubmed: 29883606
Nucleic Acids Res. 2004 Feb 23;32(4):1308-17
pubmed: 14981151

Auteurs

Damian M Janecki (DM)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Agata Swiatkowska (A)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Joanna Szpotkowska (J)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Anna Urbanowicz (A)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Martyna Kabacińska (M)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Kamil Szpotkowski (K)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Jerzy Ciesiołka (J)

Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH